Long-Term Glucose Restriction with or without β-Hydroxybutyrate Enrichment Distinctively Alters Epithelial-Mesenchymal Transition-Related Signalings in Ovarian Cancer Cells

References

• Jansen N, Walach H. The development of tumors under a ketogenic diet in association with the novel tumor marker TKTL1: a case series in general practice. Oncol Lett. 2016;11(1):584–92. doi:10.3892/ol.2015.3923
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• La Vecchia C. Ovarian cancer: epidemiology and risk factors. Eur J Cancer Prev. 2017;26(1):55–62. doi:10.1097/CEJ.0000000000000217
   PubMed Web of Science ®Google Scholar
• Riman T, Persson I, Nilsson S. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin Endocrinol (Oxf). 1998;49(6):695–707. doi:10.1046/j.1365-2265.1998.00577.x
   PubMed Web of Science ®Google Scholar
• Seyfried TN, Shelton LM. Cancer as a metabolic disease. Nutr Metab (Lond)). 2010;7(1):7. doi:10.1186/1743-7075-7-7
   PubMed Web of Science ®Google Scholar
• Zeimet AG, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, Wiedemair AM, Rumpold H, Untergasser G, Concin N, et al. Ovarian cancer stem cells. Neoplasma. 2012;59(6):747–55. doi:10.4149/neo_2012_094
   PubMed Web of Science ®Google Scholar
• Zong X, Nephew KP. Ovarian cancer stem cells: role in metastasis and opportunity for therapeutic targeting. Cancers. 2019;11(7):934. doi:10.3390/cancers11070934
   PubMed Web of Science ®Google Scholar
• Zhang J, Guo X, Chang DY, Rosen DG, Mercado-Uribe I, Liu J. CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol. 2012;25(3):456–64. doi:10.1038/modpathol.2011.170
   PubMed Web of Science ®Google Scholar
• Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 2009;27(12):2875–83. doi:10.1002/stem.236
   PubMed Web of Science ®Google Scholar
• Roy L, Bobbs A, Sattler R, Kurkewich JL, Dausinas PB, Nallathamby P, Cowden Dahl KD. CD133 Promotes adhesion to the ovarian cancer metastatic niche. Cancer Growth Metastasis. 2018;11:1179064418767882doi:10.1177/1179064418767882
   Web of Science ®Google Scholar
• Jiang H, Lin X, Liu Y, Gong W, Ma X, Yu Y, Xie Y, Sun X, Feng Y, Janzen V, et al. Transformation of epithelial ovarian cancer stemlike cells into mesenchymal lineage via EMT results in cellular heterogeneity and supports tumor engraftment. Mol Med. 2012;18:1197–208. doi:10.2119/molmed.2012.00075
   PubMed Web of Science ®Google Scholar
• Ye X, Weinberg RA. Epithelial-mesenchymal plasticity: a central regulator of cancer progression. Trends Cell Biol. 2015;25(11):675–86. doi:10.1016/j.tcb.2015.07.012
   PubMed Web of Science ®Google Scholar
• Chang WH, Lai AG. Aberrations in Notch-Hedgehog signaling reveal cancer stem cells harboring conserved oncogenic properties associated with hypoxia and immunoevasion. Br J Cancer. 2019;121(8):666–78. doi:10.1038/s41416-019-0572-9
   PubMed Web of Science ®Google Scholar
• Hao J, Zhang Y, Jing D, Li Y, Li J, Zhao Z. Role of Hippo signaling in cancer stem cells. J Cell Physiol. 2014;229(3):266–70. doi:10.1002/jcp.24455
   PubMed Web of Science ®Google Scholar
• Sari IN, Phi LTH, Jun N, Wijaya YT, Lee S, Kwon HY. Hedgehog signaling in cancer: a prospective therapeutic target for eradicating cancer stem cells. Cells. 2018;7(11):208. doi:10.3390/cells7110208
   PubMed Web of Science ®Google Scholar
• Tandon I, Waghmode A, Sharma NK. Cancer stem cells equipped with powerful hedgehog signaling and better epigenetic memory: avenues to look for cancer therapeutics. Curr Cancer Drug Targets. 2019;19(11):877–884. doi:10.2174/1568009619666190808155432
   Web of Science ®Google Scholar
• Raghavan S, Mehta P, Xie Y, Lei YL, Mehta G. Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments. J Immunother Cancer. 2019;7(1):190doi:10.1186/s40425-019-0666-1
   PubMed Web of Science ®Google Scholar
• Ceccarelli S, Megiorni F, Bellavia D, Marchese C, Screpanti I, Checquolo S. Notch3 targeting: a novel weapon against ovarian cancer stem cells. Stem Cells Int. 2019;2019:6264931doi:10.1155/2019/6264931
   PubMed Web of Science ®Google Scholar
• Pan H, Kim E, Rankin GO, Rojanasakul Y, Tu Y, Chen YC. Theaflavin-3, 3'-digallate inhibits ovarian cancer stem cells via suppressing Wnt/β-catenin signaling pathway . J Funct Foods. 2018;50:1–7. doi:10.1016/j.jff.2018.09.021
   PubMed Web of Science ®Google Scholar
• Jagust P, de Luxan-Delgado B, Parejo-Alonso B, Sancho P. Metabolism-based therapeutic strategies targeting cancer stem cells. Front Pharmacol. 2019;10:203doi:10.3389/fphar.2019.00203
   PubMed Web of Science ®Google Scholar
• Menendez JA, Joven J. Energy metabolism and metabolic sensors in stem cells: the metabostem crossroads of aging and cancer. Adv Exp Med Biol. 2014;824:117–40. doi:10.1007/978-3-319-07320-0_10
   PubMed Web of Science ®Google Scholar
• Ozsvari B, Sotgia F, Simmons K, Trowbridge R, Foster R, Lisanti MP. Mitoketoscins: novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs). Oncotarget. 2017;8(45):78340–50. doi:10.18632/oncotarget.21259
   PubMedGoogle Scholar
• Wong TL, Che N, Ma S. Reprograming of central carbon metabolism in cancer stem cells. Biochim Biophys Acta Mol Basis Dis. 2017;1863(7):1728–38. doi:10.1016/j.bbadis.2017.05.012
   PubMed Web of Science ®Google Scholar
• Fine EJ, Miller A, Quadros EV, Sequeira JM, Feinman RD. Acetoacetate reduces growth and ATP concentration in cancer cell lines which over-express uncoupling protein 2. Cancer Cell Int. 2009;9(1):14. doi:10.1186/1475-2867-9-14
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ, Cohen P, Hwang D, Peterson B, Fields T, et al. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis . Prostate. 2008;68(1):11–9. doi:10.1002/pros.20683
   PubMed Web of Science ®Google Scholar
• Magee BA, Potezny N, Rofe AM, Conyers RA. The inhibition of malignant cell growth by ketone bodies. Aust J Exp Biol Med Sci. 1979;57(5):529–39. doi:10.1038/icb.1979.54
   PubMedGoogle Scholar
• Poff A, Ari C, Arnold P, Seyfried T, D'agostino D. Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer. Int J Cancer. 2014;135(7):1711–20. doi:10.1002/ijc.28809
   PubMed Web of Science ®Google Scholar
• Shukla SK, Gebregiworgis T, Purohit V, Chaika NV, Gunda V, Radhakrishnan P, Mehla K, Pipinos II, Powers R, Yu F, et al. Metabolic reprograming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer Metab. 2014;2(1):18doi:10.1186/2049-3002-2-18
   PubMedGoogle Scholar
• Woolf EC, Curley KL, Liu Q, Turner GH, Charlton JA, Preul MC, Scheck AC. The ketogenic diet alters the hypoxic response and affects expression of proteins associated with angiogenesis, invasive potential and vascular permeability in a mouse glioma model. PLoS One. 2015;10(6):e0130357doi:10.1371/journal.pone.0130357
   PubMed Web of Science ®Google Scholar
• Hao G-W, Chen Y-S, He D-M, Wang H-Y, Wu G-H, Zhang B. Growth of human colon cancer cells in nude mice is delayed by ketogenic diet with or without omega-3 fatty acids and medium-chain triglycerides. Asian Pac J Cancer Prev. 2015;16(5):2061–8. doi:10.7314/apjcp.2015.16.5.2061
   PubMedGoogle Scholar
• Seyfried TN, Flores RE, Poff AM, D'Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis. 2014;35(3):515–27. doi:10.1093/carcin/bgt480
   PubMed Web of Science ®Google Scholar
• Chung H-Y, Park YK. Rationale, feasibility and acceptability of ketogenic diet for cancer treatment. J Cancer Prev. 2017;22(3):127–34. doi:10.15430/JCP.2017.22.3.127
   PubMed Web of Science ®Google Scholar
• Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, Frank PG, Flomenberg N, Howell A, Martinez-Outschoorn UE, et al. Ketones and lactate “fuel” tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle. 2010;9(17):3506–14. doi:10.4161/cc.9.17.12731
   PubMed Web of Science ®Google Scholar
• Cuyàs E, Corominas-Faja B, Menendez JA. The nutritional phenome of EMT-induced cancer stem-like cells. Oncotarget. 2014;5(12):3970–82. doi:10.18632/oncotarget.2147
   PubMedGoogle Scholar
• Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Howell A, Lisanti MP, Sotgia F. Ketone bodies and two-compartment tumor metabolism: stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells. Cell Cycle. 2012;11(21):3956–63. doi:10.4161/cc.22136
   PubMed Web of Science ®Google Scholar
• Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP. Ketone body utilization drives tumor growth and metastasis. Cell Cycle. 2012;11(21):3964–71. doi:10.4161/cc.22137
   PubMed Web of Science ®Google Scholar
• Cohen CW, Fontaine KR, Arend RC, Gower BA. A Ketogenic diet is acceptable in women with ovarian and endometrial cancer and has no adverse effects on blood lipids: a randomized. Controlled Trial. Nutr Cancer. 2019;72(4):1–11.
   Google Scholar
• Hamilton TC, Young RC, Ozols RF. Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Semin Oncol. 1984;11(3):285–98.
   PubMed Web of Science ®Google Scholar
• Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, Pineda M, Gindin Y, Jiang Y, Reinhold WC, et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res. 2013;73(14):4372–82. doi:10.1158/0008-5472.CAN-12-3342
   PubMed Web of Science ®Google Scholar
• Ruijter JM, Ramakers C, Hoogaars WMH, Karlen Y, Bakker O, van den Hoff MJB, Moorman AFM. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res. 2009;37(6):e45-e45. doi:10.1093/nar/gkp045
   PubMed Web of Science ®Google Scholar
• Weber DD, Aminazdeh-Gohari S, Kofler B. Ketogenic diet in cancer therapy. Aging (Albany NY)). 2018;10(2):164–5. doi:10.18632/aging.101382
   PubMedGoogle Scholar
• Skubitz APN, Taras EP, Boylan KLM, Waldron NN, Oh S, Panoskaltsis-Mortari A, Vallera DA. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol Oncol. 2013;130(3):579–87. doi:10.1016/j.ygyno.2013.05.027
   PubMed Web of Science ®Google Scholar
• Lu Z-Y, Dong R, Li D, Li W-B, Xu F-Q, Geng Y, Zhang Y-S. SNAI1 overexpression induces stemness and promotes ovarian cancer cell invasion and metastasis. Oncol Rep. 2012;27(5):1587–91. doi:10.3892/or.2012.1685
   PubMed Web of Science ®Google Scholar
• Ma L, Lai D, Liu T, Cheng W, Guo L. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Acta Biochim Biophys Sin (Shanghai)). 2010;42(9):593–602. doi:10.1093/abbs/gmq067
   PubMed Web of Science ®Google Scholar
• Singh RK, Dhadve A, Sakpal A, De A, Ray P. An active IGF-1R-AKT signaling imparts functional heterogeneity in ovarian CSC population. Sci Rep. 2016;6:36612doi:10.1038/srep36612
   PubMed Web of Science ®Google Scholar
• Wang Y, Cardenas H, Fang F, Condello S, Taverna P, et al. SGI-110 alters ovarian cancer stem cells to prevent recurrent and chemoresistant ovarian cancer. AACR, 2014.
   Google Scholar
• Liu JR, Opipari AW, Tan L, Jiang Y, Zhang Y, Tang H, Nuñez G. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res. 2002;62(3):924–31.
   PubMed Web of Science ®Google Scholar
• Hussien R, Brooks GA. Mitochondrial and plasma membrane lactate transporter and lactate dehydrogenase isoform expression in breast cancer cell lines. Physiol Genomics. 2011;43(5):255–64. doi:10.1152/physiolgenomics.00177.2010
   PubMed Web of Science ®Google Scholar
• Hernandez AR, Hernandez CM, Campos K, Truckenbrod L, Federico Q, Moon B, McQuail JA, Maurer AP, Bizon JL, Burke SN, et al. A ketogenic diet improves cognition and has biochemical effects in prefrontal cortex that are dissociable from hippocampus. Front Aging Neurosci. 2018;10:391. doi:10.3389/fnagi.2018.00391
   PubMed Web of Science ®Google Scholar
• Hernandez AR, Hernandez CM, Campos KT, Truckenbrod LM, Sakarya Y, McQuail JA, Carter CS, Bizon JL, Maurer AP, Burke SN, et al. The antiepileptic ketogenic diet alters hippocampal transporter levels and reduces adiposity in aged rats. J Gerontol A: Biol Sci Med Sci. 2018;73(4):450–8. doi:10.1093/gerona/glx193
   PubMed Web of Science ®Google Scholar
• Chang HT, Olson LK, Schwartz KA. Ketolytic and glycolytic enzymatic expression profiles in malignant gliomas: implication for ketogenic diet therapy. Nutr Metab (Lond)). 2013;10(1):47. doi:10.1186/1743-7075-10-47
   PubMed Web of Science ®Google Scholar
• Zhang J, Jia P-P, Liu Q-L, Cong M-H, Gao Y, Shi H-P, Yu W-N, Miao M-Y. Low ketolytic enzyme levels in tumors predict ketogenic diet responses in cancer cell lines in vitro and in vivo. J Lipid Res. 2018;59(4):625–34. doi:10.1194/jlr.M082040
   PubMed Web of Science ®Google Scholar
• Nylen K, Velazquez JLP, Sayed V, Gibson KM, Burnham WM, Snead OC. The effects of a ketogenic diet on ATP concentrations and the number of hippocampal mitochondria in Aldh5a1(-/-) mice. Biochim Biophys Acta. 2009;1790(3):208–12. doi:10.1016/j.bbagen.2008.12.005
   PubMed Web of Science ®Google Scholar
• Shukla SK, Chaika NV, Singh PK. Beta-hydroxybutyrate inhibits oncogenic signaling and cellular motility in pancreatic cancer cells. AACR, 2018.
   Google Scholar
• Barghout SH, Zepeda N, Xu Z, Steed H, Lee C-H, Fu YXin. Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells. Biochem Biophys Res Commun. 2015;468(1-2):173–8. doi:10.1016/j.bbrc.2015.10.138
   PubMed Web of Science ®Google Scholar
• Garcia-Jimenez C, García-Martínez JM, Chocarro-Calvo A, De la Vieja A. A new link between diabetes and cancer: enhanced WNT/β-catenin signaling by high glucose. J Mol Endocrinol. 2014;52(1):R51–R66. doi:10.1530/JME-13-0152
   PubMed Web of Science ®Google Scholar
• Mo JS, Park HW, Guan KL. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 2014;15(6):642–56. doi:10.15252/embr.201438638
   PubMed Web of Science ®Google Scholar
• Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S, Goode S. Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res. 2010;70(21):8517–25. doi:10.1158/0008-5472.CAN-10-1242
   PubMed Web of Science ®Google Scholar
• Halder G, Johnson RL. Hippo signaling: growth control and beyond. Development. 2011;138(1):9–22. doi:10.1242/dev.045500
   PubMed Web of Science ®Google Scholar
• Xia Y, Chang T, Wang Y, Liu Y, Li W, Li M, Fan H-Y. YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. PloS One. 2014;9(3):e91770doi:10.1371/journal.pone.0091770
   PubMed Web of Science ®Google Scholar
• Koo JH, Guan K-L. Interplay between YAP/TAZ and metabolism. Cell Metab. 2018;28(2):196–206. doi:10.1016/j.cmet.2018.07.010
   PubMed Web of Science ®Google Scholar
• Ke Z, Caiping S, Qing Z, Xiaojing W. Sonic hedgehog-Gli1 signals promote epithelial-mesenchymal transition in ovarian cancer by mediating PI3K/AKT pathway. Med Oncol. 2015;32(1):368doi:10.1007/s12032-014-0368-y
   PubMed Web of Science ®Google Scholar
• Dang MT, Wehrli S, Dang CV, Curran T. The ketogenic diet does not affect growth of hedgehog pathway medulloblastoma in mice. PloS One. 2015;10(7):e0133633doi:10.1371/journal.pone.0133633
   PubMed Web of Science ®Google Scholar
• Rodriguez LG, Wu X, Guan J-L. Wound-healing assay. In: Cell Migration. pp. 23–9. Totowa, NJ: Humana Press Inc., 2005.
   Google Scholar
• Zhang C, Zhang Z, Zhang S, Wang W, Hu P. Targeting of Wnt/β-catenin by anthelmintic drug pyrvinium enhances sensitivity of ovarian cancer cells to chemotherapy. Med Sci Monit. 2017;23:266–75. doi:10.12659/msm.901667
   PubMed Web of Science ®Google Scholar
• Lamkin DM, Spitz DR, Shahzad MMK, Zimmerman B, Lenihan DJ, Degeest K, Lubaroff DM, Shinn EH, Sood AK, Lutgendorf SK, et al. Glucose as a prognostic factor in ovarian carcinoma. Cancer: Interdiscipl Int J Am Cancer Soc. 2009;115(5):1021–7. doi:10.1002/cncr.24126
   Web of Science ®Google Scholar
• Priebe A, Tan L, Wahl H, Kueck A, He G, Kwok R, Opipari A, Liu JR. Glucose deprivation activates AMPK and induces cell death through modulation of Akt in ovarian cancer cells. Gynecol Oncol. 2011;122(2):389–95. doi:10.1016/j.ygyno.2011.04.024
   PubMed Web of Science ®Google Scholar
• Xu Y, Gao W, Zhang Y, Wu S, Liu Y, Deng X, Xie L, Yang J, Yu H, Su J, et al. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells. Int J Oncol. 2018;53(3):1055–68. doi:10.3892/ijo.2018.4476
   PubMed Web of Science ®Google Scholar